Tofacitinib or baricitinib (DrugBank: Tofacitinib, Baricitinib)
12 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
11 | Myasthenia | 0 |
40 | Takayasu arteritis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
84 | Sarcoidosis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04449224 (ClinicalTrials.gov) | April 27, 2020 | 7/6/2020 | Comparative Effectiveness of Targeted Therapy in RA Patients | Comparative Effectiveness of Biologic Disease-modifying Antirheumatic Drugs and Small Molecular Inhibitors in Patients With Moderate to Severe RA: Prospective Observational Study | Rheumatoid Arthritis | Drug: Adalimuab, Etanercept, Tocilizumab, or Abatacept;Drug: Tofacitinib or Baricitinib | Hanyang University | Ministry of Health, Republic of Korea | Recruiting | 19 Years | N/A | All | 506 | Korea, Republic of |